The Big Impact of Skinny Labels: What the Supreme Court’s Decision in Hikma v. Amarin May Mean for Patent Strategy

The Supreme Court will decide if a generic drug maker that omits patented uses from its label can still be liable for patent infringement based on marketing. The ruling could impact pharmaceutical ...
Medscape

Drug Labels Often Neglect to Inform About Obesity Dosing

Obesity can alter the action of many types of medications in ways affecting safety and/or efficacy, but this often isn’t mentioned in the labels. Experts in obesity and pharmacology are trying to ...
Medscape

Introduction to the New Prescription Drug Labeling by the Food and Drug Administration

A label begins with highlights, a succinct, half-page summary of the information that health care practitioners most commonly refer to and view as most important (Figure 2). [4] This section provides ...
EurekAlert!

Paper: FDA-required drug labels shouldn’t be treated as evidence of patent infringement

Drug labels required by the U.S. Food and Drug Administration are intended to guide the safe and effective use of prescription drugs, but the overzealous and hyperbolic claims of patent infringement ...
Managing Intellectual Property

Patent infringement and skinny labels: Taiwan judgments on generic drug indication carve-outs

Bruce Huang of Saint Island International Patent & Law Offices explains how the Intellectual Property and Commercial Court and the Supreme Court have recently clarified limits on generic drug skinny-l ...